{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-009483","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.507586+00:00","generated_at":"2026-06-27T00:15:08.801191+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Achieve Life Sciences reports FY2021 net loss $33.2M; Phase 3 ORCA-2 topline data expected Q2 2022","bullets":["Cash, cash equivalents and restricted cash of $43.1M as of Dec 31, 2021.","Total operating expenses for FY2021 were $33.1M; net loss $33.2M.","Initiated Phase 3 ORCA-3 trial; ORCA-2 completed with topline results due Q2 2022.","Entered $25M loan facility with Silicon Valley Bank in December 2021.","FDA accepted IND for cytisinicline in e-cigarette/vaping cessation; Phase 2 ORCA-V1 expected Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-009483","json":"https://secwatch.observer/filing/0001564590-22-009483.json","markdown":"https://secwatch.observer/filing/0001564590-22-009483.md","text":"https://secwatch.observer/filing/0001564590-22-009483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000156459022009483/0001564590-22-009483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000156459022009483/achv-8k_20220310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:15:08.801191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}